No Data
William Blair Maintains UniQure NV(QURE.US) With Buy Rating
William Blair analyst Sami Corwin maintains $uniQure NV(QURE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 37.2% and a total average return of -4.6% over the pas
Sector Update: Health Care Stocks Mixed Premarket Monday
UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE
Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE
UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease